Thousands of women across the United States have filed a depo provera lawsuit after developing meningioma brain tumors they say are linked to the contraceptive injection. The litigation, built around a widely cited 2024 medical study, moved at unusual speed through the federal courts and reached a global settlement in principle in mid-2026. This guide explains what Depo-Provera is, what the science actually found, where the depo lawsuit stands in October 2026, and what the settlement means for women who may have a claim.
The quick answer: The Depo Provera lawsuit is a federal mass tort (MDL No. 3140) in Florida accusing Pfizer of failing to warn that long-term use of its contraceptive injection raises meningioma brain tumor risk, per a 2024 BMJ study. A settlement was signed in July 2026, and registration closes November 30, 2026.
What Is Depo-Provera?
Depo-Provera is the brand name for depot medroxyprogesterone acetate (DMPA), a long-acting progestin-only contraceptive injection. It is typically given as a 150 mg shot every three months and has been marketed in the United States since 1992. Pfizer is the manufacturer of the brand-name product, and generic versions containing the same active ingredient are also on the market.
The shot has been used by tens of millions of women worldwide, often for years at a time, as a convenient alternative to daily birth control pills. For decades it was prescribed routinely without any mention of a brain tumor risk. The lawsuits now allege that the connection to meningioma was knowable long before patients were warned, and that the company failed in its duty to inform patients and doctors.
The Meningioma Link: What the 2024 BMJ Study Actually Found
The scientific centerpiece of the depo provera lawsuit is a study published in The BMJ in March 2024 by Roland and colleagues. It was a national case-control study using the French national health data system, and it examined the link between several widely used progestogens and intracranial meningioma.
The numbers were striking. Researchers analyzed 18,061 women who had undergone intracranial surgery for meningioma and compared them with 90,305 control women matched by year of birth and area of residence. Among the cases, 9 women had been exposed to injectable medroxyprogesterone acetate 150 mg (0.05%), compared with 11 exposed controls (0.01%). That translated into an odds ratio of 5.55, often rounded in news coverage to a 5.6-fold increased risk.
Two details matter. First, the excess risk appeared to be driven by prolonged use of one year or more, with the strongest signal after three or more years of exposure. Use of less than a year showed no excess risk. Second, the study was observational, which means it can show an association but cannot by itself prove that the drug caused the tumors. The absolute numbers were also small, with only 9 exposed cases among more than 18,000, which is why researchers and litigators alike treat the findings as a strong signal rather than a closed question.
Regulators moved after the study appeared. The European Medicines Agency added meningioma as a possible side effect in 2024, and labels were updated in Canada and New Zealand around the same time. In the United States, the FDA did not approve a meningioma warning for the Depo-Provera label until December 2025, more than three decades after the drug was first approved.
What the Lawsuits Allege
The core allegation in the depo provera lawsuit is failure to warn. Plaintiffs allege that Pfizer knew, or should have known, that long-term Depo-Provera use substantially raised the risk of meningioma brain tumors, but did not adequately warn U.S. patients and their doctors.
Plaintiffs point to several supporting arguments. International regulators flagged progestin-related meningioma concerns years before the U.S. label changed, and Pfizer added meningioma warnings to Depo-Provera labeling in other countries well before the U.S. label was updated. The lawsuits argue that American women were left exposed to a risk that was disclosed elsewhere.
Pfizer has pushed back with a federal preemption defense. The company has argued that the FDA rejected a label update it submitted in 2024 that would have included meningioma information, and that federal law therefore barred it from adding the warning on its own. That defense took a major hit when the FDA approved a new label with a meningioma warning at the end of 2025. Pfizer has not admitted wrongdoing, and none of the settlement developments discussed below change that.
It is important to note what these cases are not. Many people search for a “depo provera class action,” but the litigation is not technically a class action. It is a multidistrict litigation, or MDL, in which each woman keeps her own individual case while shared pretrial steps are coordinated before a single judge.
Timeline of Key Events
| Date | Event |
|---|---|
| 1992 | The FDA approves Depo-Provera for use in the United States. Pfizer markets the injectable contraceptive for decades without a meningioma warning. |
| March 2024 | The BMJ publishes the Roland et al. French case-control study, reporting an odds ratio of 5.55 for intracranial meningioma with injectable medroxyprogesterone acetate. |
| 2024 | The European Medicines Agency adds meningioma as a possible side effect, and labels are updated in Canada and New Zealand. Pfizer argues the FDA rejected a similar U.S. label update. |
| Late 2024 | Individual lawsuits begin appearing nationwide as women connect meningioma diagnoses to long-term Depo-Provera use. |
| February 7, 2025 | The Judicial Panel on Multidistrict Litigation creates MDL No. 3140, In re: Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, in the U.S. District Court for the Northern District of Florida before Judge M. Casey Rodgers. |
| March 2025 | The new MDL opens with 78 pending cases. |
| December 2025 | The FDA approves a new U.S. Depo-Provera label that warns of a potential connection to meningiomas, more than 30 years after approval. |
| April 2026 | Federal cases in the MDL reach roughly 3,490. |
| June 1, 2026 | The JPML report counts 5,508 pending cases in the MDL, a record one-month jump. |
| June 15, 2026 | Pfizer and plaintiffs’ leadership announce a global settlement in principle. The December 7, 2026 bellwether trial comes off the calendar. |
| July 21, 2026 | The parties sign a Master Settlement Agreement. Its terms are confidential. |
| July 27, 2026 | Judge Rodgers approves the settlement administration procedures at a case management conference in Pensacola. |
| August 2026 | BrownGreer PLC is appointed settlement administrator. About 6,300 cases are pending, and the parties estimate roughly 80 percent of MDL plaintiffs will be eligible under the agreement. |
| September 9, 2026 | Judge Rodgers appoints Matt Garretson of Garretson, LLC as Allocation Master for the Supplemental Compensation Fund and CPA Randall Sansom to administer the Qualified Settlement Fund. |
| October 5, 2026 | The MDL count reaches 6,412 pending lawsuits. New filings continue even as the settlement registration process moves forward. |
| November 30, 2026 | Registration deadline for plaintiffs to take part in the settlement program (upcoming). |
| First quarter of 2027 | First payments to qualifying claimants are projected to begin (projection, not a guarantee). |
Depo Provera Lawsuit Update: Where the MDL Stands in October 2026
All federal Depo-Provera meningioma claims are consolidated in MDL No. 3140 before Judge M. Casey Rodgers in the Northern District of Florida. The docket grew at a staggering pace: from 78 cases in March 2025 to about 3,490 by April 2026, to 5,508 by June 2026, and to 6,412 by early October 2026. Hundreds of additional cases sit in state courts in states including New York, Delaware, and California, where some claims are still moving forward on expert challenges, preemption motions, and discovery.
The June 2026 agreement in principle changed the trajectory of the federal litigation. The first bellwether trial, previously scheduled for December 7, 2026, was vacated, and the general-causation hearing was reset as the parties turned to administration. Judge Rodgers also built a separate litigation track for plaintiffs who do not participate in the settlement, whether they are deemed ineligible, decline the deal, or file later. That track carries demanding proof requirements, including a case-specific expert report addressing causation and alternative causes.
The Depo Provera Settlement: What Is Confirmed
On June 15, 2026, plaintiffs’ lead counsel and the Pfizer defendants announced they had reached a global settlement in principle. Judge Rodgers confirmed it by court order, and the parties signed a confidential Master Settlement Agreement on July 21, 2026. Here is what is confirmed about the depo provera settlement, and what is not.
Confirmed: BrownGreer PLC serves as the settlement administrator, registration is expected to be completed in November 2026, and the deadline for plaintiffs to register is November 30, 2026. Payments are projected to begin in the first quarter of 2027, though those dates are projections and can change. The parties have estimated that roughly 80 percent of MDL plaintiffs would be eligible, and Pfizer has not admitted wrongdoing.
Not confirmed: the eligibility criteria and the individual payout amounts are confidential. Court reporting has been explicit that any specific payment figure published before the terms are released is an estimate, not a confirmed settlement amount. Be cautious of unsolicited calls, texts, or websites claiming to register women for the settlement; legitimate updates come through the court, the administrator, or a chosen law firm.
Approximately one in five filed cases is expected to fall outside the deal, many because of timing issues with filing deadlines. Women in that group, and women who have not yet filed, may still have viable individual claims depending on their Depo-Provera use history and diagnosis, but they face stricter proof requirements going forward.
Depo Provera Lawsuit Qualifications
Litigation sources describe several criteria that generally define who may have a claim, though the formal eligibility criteria under the confidential settlement have not been published. The widely discussed depo provera lawsuit qualifications are:
First, the woman received Depo-Provera injections, or generic medroxyprogesterone acetate shots, for at least one year. The BMJ study found no excess meningioma risk for use under a year, and the litigation focuses on prolonged use. Second, she was diagnosed with a meningioma, confirmed by MRI imaging or surgical pathology. Meningioma is a tumor of the membranes surrounding the brain and spinal cord; most are benign, but they can cause serious neurological problems when they grow or press on the brain. Third, she had no pre-existing brain tumor before her Depo-Provera use.
Key evidence typically includes injection records, MRI reports, neurosurgical or pathology notes, and related treatment records. Because meningioma warning signs can be subtle, sources describe symptoms such as chronic or worsening headaches, vision changes, seizures, cognitive or memory impairment, and balance or hearing problems as reasons to see a doctor. Anyone experiencing these symptoms should seek medical evaluation, not a lawyer first.
What About a Depo Lawsuit Payout?
The most asked question is about money, and the honest answer is that no depo lawsuit payout amounts have been made public. The Master Settlement Agreement is confidential, the payout matrix has not been released, and reporting on the litigation stresses that published dollar figures are estimates rather than confirmed amounts. Anyone promising a specific payment is not describing verified terms.
That said, in mass tort settlement programs, individual compensation typically varies with factors like the severity of the injury, whether surgery was required, age at diagnosis, lost wages and medical costs, and ongoing medical needs. The settlement structure includes a Supplemental Compensation Fund with an appointed Allocation Master, which suggests the program will weigh individual circumstances rather than paying every claimant the same amount.
The practical takeaway: women who filed before the registration deadline and meet the (still confidential) eligibility rules are expected to have their claims reviewed by the administrator, with decisions to follow and payments projected for the first quarter of 2027. Nothing is guaranteed, and the litigation track remains for those outside the deal.
Frequently Asked Questions
Is the Depo-Provera lawsuit a class action?
No. Although people commonly search for a depo provera class action, the cases are consolidated in a federal multidistrict litigation, MDL No. 3140, in the Northern District of Florida. In an MDL each plaintiff keeps her own individual case and may receive compensation based on her own circumstances, rather than sharing a single class recovery.
What did the 2024 BMJ study find about Depo-Provera and meningioma?
The French national case-control study found that women exposed to injectable medroxyprogesterone acetate 150 mg had an odds ratio of 5.55 for intracranial meningioma requiring surgery, about a 5.6-fold increased risk. The excess risk was driven by prolonged use of one year or more. The study was observational, so it shows an association rather than proving causation, and only 9 of the 18,061 surgical cases had been exposed.
Has the Depo-Provera settlement been finalized?
A Master Settlement Agreement was signed on July 21, 2026, and settlement administration is underway with BrownGreer PLC as administrator. However, the agreement’s eligibility criteria and payout amounts remain confidential. Registration closes November 30, 2026, and payments are projected to begin in the first quarter of 2027, though these dates are projections.
Who qualifies for the Depo-Provera lawsuit?
The criteria discussed in the litigation generally include Depo-Provera or generic medroxyprogesterone acetate injections for at least one year, a meningioma diagnosis confirmed by MRI or pathology, and no pre-existing brain tumor. The formal eligibility criteria under the confidential settlement have not been published.
How much will Depo-Provera lawsuit payouts be?
No payout amounts have been confirmed. The settlement terms are confidential, and litigation reporting explicitly warns that any published dollar figure is an estimate, not a confirmed amount. Individual compensation is expected to vary with injury severity, surgery, and medical costs, but the payout matrix has not been released.
Can I still file a Depo-Provera lawsuit?
New filings continue to enter federal and state courts, and some women outside the settlement criteria may still have viable individual claims. However, roughly one in five filed cases is expected to fall outside the settlement, often over filing-deadline issues, and the separate litigation track carries demanding proof requirements. Filing deadlines vary by state, so prompt evaluation matters.
Did Pfizer admit wrongdoing in the settlement?
No. Pfizer has not admitted wrongdoing, which is standard in mass tort settlements. The company continues to press its federal preemption defense, arguing it could not add the meningioma warning because the FDA had rejected its proposed label update in 2024, though that argument weakened after the FDA approved a warning label in December 2025.
Related Articles
- How Is Liability Established in a Dog Bite Case? (2026 Guide)
- What Is a Registered Agent for LLC? Duties, Requirements, and Cost
- Sole Proprietorship vs LLC: Which Is Right for Your Business in 2026?
- Assessing Water Damage: What to Look For (2026 Homeowner Guide)
The Bottom Line
The depo provera lawsuit has moved from a 2024 medical study to one of the fastest-growing federal mass torts, with more than 6,400 cases in MDL No. 3140 and a confidential Pfizer settlement in administration. If you or someone you know used Depo-Provera for a year or more and later developed a meningioma, the November 30, 2026 registration deadline matters, and the details should be checked through official court or administrator channels rather than solicitation calls. Stay informed with the latest reporting at digitalgeekspot.com.
